Amarin investors rejoiced this summer after the company’s drug, Vascepa, which is derived from a fish oil compound, was approved by the FDA. As a result, Amarin’s share price has nearly doubled in value since the start of 2012, and the company is poised to market the drug in early 2013. Vascepa will compete with GlaxoSmithKline’s triglyceride-lowering therapeutic Lovaza, which generated more than $900 million in sales for fiscal 2011.

However, recent studies challenge the notion that fish oil has positive benefits for the cardiovascular system. Does this news put Amarin’s future drug sales in jeopardy? Healthcare bureau chief Brenton Flynn, and analyst Max Macaluso, discuss the news in the video below.

 

Amarin has had a great run so far this year, but it didn’t make our list of the three Middle-Class Millionaire-Makers that Wall Street’s too rich to notice. These stocks might be ignored by the 1%, but they could boost the returns in your portfolio -- just click here to read it now.